Seres Therapeutics Names Berenson to its Board of Directors
8 August 2019 - - US-based microbiome therapeutics platform company Seres Therapeutics, Inc. (NASDAQ: MCRB) TODAY appointed Stephen Berenson to its board of directors, the company said.

Berenson is a managing partner at Flagship Pioneering and previously spent his career as an investment banker at J.P. Morgan.

Prior to Flagship, Berenson spent 33 years in various roles as an investment banker at J.P. Morgan.

During his last 12 years at J.P. Morgan, Berenson was vice chairman of Investment Banking, where he focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally.

He was co-founder of J.P. Morgan's Global Strategic Advisory Council and co-founder of the firm's Board Initiative.

Berenson also serves on the board of directors of Moderna, Inc. and CiBO Technologies, Inc. Berenson received an S.B. in mathematics from Massachusetts Institute of Technology.

Seres Therapeutics is a microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced.

The company's SER-287 programme has obtained Fast Track and Orphan Drug designation from the US Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis.

Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficileinfection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma.